Meta-analysis of influences of Biejiajian Pill combined with entecavir on serum liver fibrosis markers of compensatory period of hepatitis b cirrhosis
| Autor: | Long Wang, Yu Yang, Xiuli Zheng, Jinyu Shi, Xianrong Feng, Baojia Wang, Tianyao Zhang, Guiyu Li, Ning Cao |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Liver Cirrhosis
medicine.medical_specialty Guanine Cirrhosis Traditional Chinese medicine Cochrane Library hepatitis b cirrohsis Antiviral Agents law.invention 03 medical and health sciences 0302 clinical medicine Randomized controlled trial law Internal medicine Study Protocol Systematic Review medicine Humans 030212 general & internal medicine biejiajian pill liver fibrosis markers in scrum business.industry General Medicine Entecavir Hepatitis B medicine.disease 030220 oncology & carcinogenesis Pill Drug Therapy Combination Liver function business Biomarkers Drugs Chinese Herbal Systematic Reviews as Topic Research Article entecavir medicine.drug |
| Zdroj: | Medicine |
| ISSN: | 1536-5964 0025-7974 |
| DOI: | 10.1097/md.0000000000018458 |
| Popis: | Background: Chronic viral hepatitis b and its related complications have caused serious harm to human health and become a worldwide public health problem. Hepatitis b cirrhosis is one of the most common complications in Asia. Traditional Chinese medicine combined with antiviral therapy has become the first choice for clinical treatment of hepatitis b Cirrhosis. Biejia Pill is an effective prescription of traditional Chinese medicine in treating Compensatory period of cirrhosis, and there are more and more clinical reports about its validity in treating Compensatory period of cirrhosis. Therefore, we designed this study protocol to evaluate the adjuvant role of Biejia Pill in the treatment of Compensatory period of cirrhosis. Method: Electronic Databases, PubMed, EMBASE database, Cochrane Library, China National Knowledge Infrastructure (CNKI), Wan Fang, Chinese Scientific Journals Database (VIP) and China Biology Medicine disc, (CBM), will be systematically searched from inception to July 2019. Randomized controlled trials (RCTs) on Biejiajian Pill combined with Entecavir and Entecavir alone against Compensatory period of hepatitis b cirrhosis will be included; inclusion and exclusion criteria will be used to screen the trials. liver fibrosis biomarkers including ECM or its metabolites (serum hyaluronic acid (HA), laminin (LN), procollagen type III (PC-III), and type IV collagen (IV-C)) will be measured as primary outcomes. Liver function, including alanine aminotransferase (ALT) and aspartarte aminotransferase (AST), and improvement of related clinical symptoms will be measured as secondary outcomes. RevMan5 software will be used for literature quality evaluation and data synthesis and analysis. Result: To evaluate the efficacy and safety of Biejiajian Pill in combination therapy by observing the outcomes of serum liver fibrosis markers, adverse reactions and liver function. Conclusion: This study protocol will be used to evaluate the efficacy and safety of Biejia Pill in combination with entecavir in the treatment of Compensatory period of hepatitis b cirrhosis, as well as the adjuvant treatment of Biejia Pill in combination. PROSPERO registration number: CRD42019135402 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|